Seagen Inc. which can be found using ticker (SGEN) have now 11 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The target price High/Low ranges between $229.00 and $228.00 with the average target price sitting at $228.91. Given that the stocks previous close was at $213.52 and the analysts are correct then we can expect a percentage increase in value of 7.2%. It’s also worth noting that there is a 50 day moving average of $213.91 and the 200 day moving average is $199.96. The total market capitalization for the company now stands at 40.22B. The stock price is currently at: $213.21 USD
The potential market cap would be $43,124,150,056 based on the market consensus.
The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of $12.29 and a -12.94% return on assets.
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
